Scientific research has gifted us with a range of evidence-based options to protect ourselves from getting infected with HIV.

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

Anal cancer screening among men who have sex with men with HIV aged 35 years and older appeared cost-effective and could decrease anal cancer incidence and mortality, according to research published ...

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

Strategy may lead to new ... effective in preventing HIV. Strategy may lead to new vaccines that only need to be taken once. Vishwam Sankaran. Thursday 19 June 2025 12:03 BST. Comments. FDA ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or ...

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...